Linked Life Data

18695440

Source:http://linkedlifedata.com/resource/pubmed/id/18695440

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18695440rdf:typepubmed:Citationlld:pubmed
pubmed-article:18695440lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C1956346lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C1442837lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C0021107lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C0253563lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C0205219lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C1696465lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C2348535lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C1322815lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:18695440lifeskim:mentionsumls-concept:C0950902lld:lifeskim
pubmed-article:18695440pubmed:issue9lld:pubmed
pubmed-article:18695440pubmed:dateCreated2008-8-12lld:pubmed
pubmed-article:18695440pubmed:abstractTextDespite the availability of several potent antithrombotic agents, the optimal antiplatelet regimen in elective patients undergoing complex percutaneous coronary interventions is still debated. Aim of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial will be to assess the safety and efficacy of routine usage of the glycoprotein IIb/IIIa inhibitor eptifibatide in patients already treated with aspirin and clopidogrel and undergoing implantation of at least two drug-eluting stents in the same lesion, thus identifying a clinically stable but anatomically complex patient subset.lld:pubmed
pubmed-article:18695440pubmed:languageenglld:pubmed
pubmed-article:18695440pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18695440pubmed:citationSubsetIMlld:pubmed
pubmed-article:18695440pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18695440pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18695440pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18695440pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18695440pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18695440pubmed:statusMEDLINElld:pubmed
pubmed-article:18695440pubmed:monthSeplld:pubmed
pubmed-article:18695440pubmed:issn1558-2027lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:ColomboAntoni...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:MargheriMassi...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:Biondi-Zoccai...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:RomeoFrancesc...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:SangiorgiGius...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:VioliniRobert...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:PratiFrancesc...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:SheibanImadIlld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:MarzocchiAnto...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:ValgimigliMar...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:SardellaGenna...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:LettieriCorra...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:ClementiFabri...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:VischiMassimo...lld:pubmed
pubmed-article:18695440pubmed:authorpubmed-author:StabileAmerig...lld:pubmed
pubmed-article:18695440pubmed:issnTypePrintlld:pubmed
pubmed-article:18695440pubmed:volume9lld:pubmed
pubmed-article:18695440pubmed:ownerNLMlld:pubmed
pubmed-article:18695440pubmed:authorsCompleteYlld:pubmed
pubmed-article:18695440pubmed:pagination957-62lld:pubmed
pubmed-article:18695440pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:meshHeadingpubmed-meshheading:18695440...lld:pubmed
pubmed-article:18695440pubmed:year2008lld:pubmed
pubmed-article:18695440pubmed:articleTitleA randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.lld:pubmed
pubmed-article:18695440pubmed:affiliationInterventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy.lld:pubmed
pubmed-article:18695440pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18695440pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18695440pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18695440pubmed:publicationTypeMulticenter Studylld:pubmed